OC12 | THYMOQUINONE COUNTERACTS PAINFUL PACLITAXEL-INDUCED PERIPHERAL NEUROPATHY WHILE PRESERVING ANTICANCER ACTIVITY: INSIGHTS FROM IN VITRO AND IN VIVO MODELS
European Journal of Histochemistry · 20.11.2026 · 70 (s2)
DOI: 10.4081/ejh.2026.4806 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Histochemistry, online erschienen am 20.11.2026. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Chemotherapy-induced peripheral neuropathy (CIPN) is a major dose-limiting toxicity of paclitaxel (PTX) that frequently necessitates dose reduction or treatment discontinuation, and no effective preventive therapy is currently available. Owing to its antioxidant and anti-inflammatory properties, thymoquinone (TQ), the principal bioactive constituent of Nigella sativa, has emerged as a potential neuroprotective agent. The neuroprotective potential of TQ was first investigated in vitro in embryonic (E15) dorsal root ganglia (DRG) from Sprague–Dawley rats, in which PTX-induced neurotoxicity was quantified by neurite outgrowth analysis. To gain mechanistic insight, SIRT1 protein expression was assessed by western blot, whereas the influence of TQ on PTX cytotoxicity was evaluated in MCF-7 and MDA-MB-231 breast cancer cells using the MTT assay. Chronic neuropathy was subsequently induced in rats by intravenous PTX administration (10 mg/kg, once weekly for 4 weeks), with concomitant oral TQ treatment (5 or 10 mg/kg/day). The effects of TQ on peripheral neuropathy were evaluated through behavioural testing, neurophysiological recordings, and histological analysis of intraepidermal nerve fibre (IENF) density, DRG, and peripheral nerves. In vitro, TQ (5 µM) significantly attenuated PTX-induced neurite shortening at 24 h and completely prevented PTX-induced SIRT1 downregulation in DRG neurons. Notably, TQ did not compromise the cytotoxic activity of PTX in MCF-7 cells and significantly potentiated it in triple-negative MDA-MB-231 cells. In vivo, PTX administration resulted in mild erythroid myelosuppression at the end of treatment. TQ consistently prevented the development of PTX-induced mechanical allodynia throughout the treatment period, and the higher dose (10 mg/kg) transiently attenuated IENF loss at mid-treatment. Nevertheless, neither neurophysiological parameters nor peripheral nerve morphology were improved at either time point. Collectively, these findings indicate that TQ mainly alleviates PTX-induced neuropathic pain rather than preventing the underlying structural damage to peripheral nerves during chronic PTX treatment.
Zitieren
APA
(2026). OC12 | THYMOQUINONE COUNTERACTS PAINFUL PACLITAXEL-INDUCED PERIPHERAL NEUROPATHY WHILE PRESERVING ANTICANCER ACTIVITY: INSIGHTS FROM IN VITRO AND IN VIVO MODELS. European Journal of Histochemistry, 70(s2). https://doi.org/10.4081/ejh.2026.4806
Vancouver
OC12 | THYMOQUINONE COUNTERACTS PAINFUL PACLITAXEL-INDUCED PERIPHERAL NEUROPATHY WHILE PRESERVING ANTICANCER ACTIVITY: INSIGHTS FROM IN VITRO AND IN VIVO MODELS. European Journal of Histochemistry. 2026;70(s2). doi:10.4081/ejh.2026.4806
BibTeX
@article{euvimed2026,
title = {OC12 | THYMOQUINONE COUNTERACTS PAINFUL PACLITAXEL-INDUCED PERIPHERAL NEUROPATHY WHILE PRESERVING ANTICANCER ACTIVITY: INSIGHTS FROM IN VITRO AND IN VIVO MODELS},
journal = {European Journal of Histochemistry},
year = {2026},
volume = {70},
number = {s2},
doi = {10.4081/ejh.2026.4806}
}
EUVIMED